Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 23, 2023 - Issue 5
Submit an article Journal homepage
340
Views
1
CrossRef citations to date
0
Altmetric
Review

Current and emerging diagnostic and management approaches for idiopathic intracranial hypertension

Ravi Piccusa Medical school, University of Birmingham, Birmingham, UKView further author information
,
Mark Thallerb Translational Brain Science, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK;c Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK;d Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UKORCID Iconhttps://orcid.org/0000-0001-7772-2157View further author information
ORCID Icon,
Alexandra J Sinclairb Translational Brain Science, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK;c Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK;d Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, UKORCID Iconhttps://orcid.org/0000-0003-2777-5132View further author information
ORCID Icon &
Susan P Mollanb Translational Brain Science, Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, UK;e Birmingham Neuro-Ophthalmology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6314-4437View further author information
ORCID Icon
Pages 457-466 | Received 23 Dec 2022, Accepted 20 Apr 2023, Published online: 28 Apr 2023

  • Wang MTM, Bhatti MT, Danesh-Meyer HV. Idiopathic intracranial hypertension: pathophysiology, diagnosis and management. J Clin Neurosci. 2022 Jan;95:172–179. Epub 2021 Dec 17. PMID: 34929642. DOI:10.1016/j.jocn.2021.11.029
  • Andrews LE, Liu GT, Ko MW. Idiopathic intracranial hypertension and obesity. Horm Res Paediatr. 2014;81(4):217–225.
  • Mollan SP, Aguiar M, Evison F, et al. The expanding burden of idiopathic intracranial hypertension. Eye. 2019;33(3):478–485.
  • Adderley NJ, Subramanian A, Nirantharakumar K, et al. Association between idiopathic intracranial hypertension and risk of cardiovascular diseases in women in the United Kingdom. JAMA Neurol. 2019 Sep 1;76(9):1088–1098. DOI:10.1001/jamaneurol.2019.1812.
  • Brahma VL, Snow J, Tam V, et al. Socioeconomic and geographic disparities in idiopathic intracranial hypertension. Neurology. 2021 Jun 8Epub 2021 May 12;96(23):e2854–2860.
  • Rehder D. Idiopathic intracranial hypertension: review of clinical syndrome, imaging findings, and treatment. Curr Probl Diagn Radiol. 2020 May;49(3):205–214. DOI:10.1067/j.cpradiol.2019.02.012.
  • Sinclair AJ, Ball AK, Burdon MA, et al. Exploring the pathogenesis of IIH: an inflammatory perspective. J Neuroimmunol. 2008 Sep 15Epub 2008 Aug 3;201-202:212–220. DOI:10.1016/j.jneuroim.2008.06.029.
  • Friedman DI, Liu GT, Digre KB. Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children. Neurology. 2013 Sep;81(13):1159–1165.
  • Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. [Epub 2018 Jun 14] 2018 Oct;89(10):1088–1100. DOI:10.1136/jnnp-2017-317440.
  • McCluskey G, Doherty-Allan R, McCarron P, et al. Meta-analysis and systematic review of population-based epidemiological studies in idiopathic intracranial hypertension. Eur J Neurol. 2018;25(10):1218–1227.
  • Thaller M, Homer V, Hyder Y, et al. The idiopathic intracranial hypertension prospective cohort study: evaluation of prognostic factors and outcomes. J Neurol. 2022;270(2):851–863. DOI:10.1007/s00415-022-11402-6
  • Goudie C, Shah P, McKee J, et al. The incidence of idiopathic intracranial hypertension in Scotland: a SOSU study. Eye (Lond). [Epub 2019 Apr 30] 2019 Oct 33(10):1570–1576. DOI:10.1038/s41433-019-0450-y
  • Miah L, Strafford H, Fonferko-Shadrach B, et al. Incidence, prevalence and healthcare outcomes in idiopathic intracranial hypertension: a population study. Neurology. 2021 Jan 20;96(8):e1251–61. Epub ahead of print. DOI:10.1212/WNL.0000000000011463
  • Kilgore KP, Lee MS, Leavitt JA, et al. Re-evaluating the incidence of idiopathic intracranial hypertension in an era of increasing obesity. Ophthalmol. [Epub 2017 Feb 7] 2017 May 124(5):697–700. DOI:10.1016/j.ophtha.2017.01.006
  • Matthews YY, Dean F, Lim MJ, et al. Pseudotumor cerebri syndrome in childhood: incidence, clinical profile and risk factors in a national prospective population-based cohort study. Arch Dis Child. 2017;102(8):715–721.
  • Apperley L, Kumar R, Senniappan S. Idiopathic intracranial hypertension in children with obesity. Acta Paediatr. [Epub 2022 Mar 27] 2022 Jul;111(7):1420–1426. DOI:10.1111/apa.16343.
  • Lyons HS, Mollan SLP, Liu GT, et al. Different characteristics of pre-pubertal and post-pubertal idiopathic intracranial hypertension: a narrative review. Neuro-Ophthalmology. 2022;47(2):63–74.
  • Mollan SP, Ali F, Hassan-Smith G, et al. Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management. J Neurol Neurosurg Psychiatry. 2016;87(9):982–992.
  • Alimajstorovic Z, Westgate CSJ, Jensen RH, et al. Guide to preclinical models used to study the pathophysiology of idiopathic intracranial hypertension. Eye. 2020;34(8):1321–1333.
  • MacAulay N, Keep RF, Zeuthen T. Cerebrospinal fluid production by the choroid plexus: a century of barrier research revisited. Fluids Barriers CNS. 2022 Mar 22;19(1):26. DOI:10.1186/s12987-022-00323-1.
  • Eide PK, Pripp AH, Ringstad G, et al. Impaired glymphatic function in idiopathic intracranial hypertension. Brain Commun. 2021 Mar 21;3(2):fcab043. DOI:10.1093/braincomms/fcab043.
  • Eide PK, Hansson HA. A new perspective on the pathophysiology of idiopathic intracranial hypertension: role of the glia-neuro-vascular interface. Front Mol Neurosci. 2022 Jul 12;15:900057. DOI:10.3389/fnmol.2022.900057.
  • Tuță S. Cerebral venous outflow implications in idiopathic intracranial hypertension-from physiopathology to treatment. Life (Basel). 2022 Jun 8;12(6):854. DOI:10.3390/life12060854.
  • Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes, including amyloid β. Sci Transl Med. 2012 Aug 15;4(147):147ra111. DOI:10.1126/scitranslmed.3003748.
  • O’Reilly MW, Westgate CSJ, Hornby C, et al. A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. JCI Insight. 2019 Mar 21;4(6):e125348. DOI:10.1172/jci.insight.125348.
  • Botfield HF, Uldall MS, Westgate CSJ, et al. A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus. Sci Transl Med. 2017;9(404). DOI:10.1126/scitranslmed.aan0972
  • Stiebel-Kalish H, Eyal S, Steiner I. The role of aquaporin-1 in idiopathic and drug-induced intracranial hypertension. Med Hypotheses. 2013;81(6):1059–1062.
  • Uldall M, Bhatt DK, Kruuse C, et al. Choroid plexus aquaporin 1 and intracranial pressure are increased in obese rats: towards an idiopathic intracranial hypertension model? Int J Obes. 2017;41(7):1141–1147. DOI:10.1038/ijo.2017.83
  • Eide PK, Hasan-Olive MM, Hansson HA, et al. Increased occurrence of pathological mitochondria in astrocytic perivascular endfoot processes and neurons of idiopathic intracranial hypertension. J Neurosci Res. [Epub 2020 Oct 26] 2021 Feb;99(2):467–480. DOI:10.1002/jnr.24743.
  • Nicholson P, Brinjikji W, Radovanovic I, et al. Venous sinus stenting for idiopathic intracranial hypertension: a systematic review and meta-analysis. J Neurointerv Surg. 2019 Apr;11(4):380–385. DOI:10.1136/neurintsurg-2018-014172.
  • Zhao K, Gu W, Liu C, et al. Advances in the understanding of the complex role of venous sinus stenosis in idiopathic intracranial hypertension. J Magn Reson Imaging. [Epub 2022 Mar 31] 2022 Sep 56(3):645–654. DOI:10.1002/jmri.28177
  • Gurney SP, Ramalingam S, Thomas A, et al. Exploring the current management idiopathic intracranial hypertension, and understanding the role of dural venous sinus stenting. Eye Brain. 2020 Jan 14;12:1–13. DOI:10.2147/EB.S193027.
  • Tian Y, Zhang Z, Jing J, et al. Anatomic variation of the lateral sinus in patients with idiopathic intracranial hypertension: delineation with black-blood contrast-enhanced MRI. Front Neurol. 2021 Nov 25;12:715857. DOI:10.3389/fneur.2021.715857.
  • Rohr A, Dörner L, Stingele R, et al. Reversibility of venous sinus obstruction in idiopathic intracranial hypertension. AJNR Am J Neuroradiol. 2007 Apr;28(4):656–659.
  • Buell TJ, Raper DMS, Pomeraniec IJ, et al. Transient resolution of venous sinus stenosis after high-volume lumbar puncture in a patient with idiopathic intracranial hypertension. J Neurosurg. [Epub 2017 Aug 25] 2018 Jul;129(1):153–156. DOI:10.3171/2017.3.JNS163181.
  • Eshtiaghi A, Zaslavsky K, Nicholson P, et al. Extent of transverse sinus stenosis does not predict visual outcomes in idiopathic intracranial hypertension. Eye (Lond). [Epub 2021 Jun 28] 2022 Jul 36(7):1390–1395. DOI:10.1038/s41433-021-01651-6
  • Khunte M, Chen H, Colasurdo M, et al. National trends of cerebral venous sinus stenting for the treatment of idiopathic intracranial hypertension. Neurology. 2023. DOI:10.1212/WNL.0000000000207245. Mar 29:10.1212/WNL.0000000000207245.
  • Grech O, Mollan SP, Wakerley BR, et al. Emerging themes in idiopathic intracranial hypertension. J Neurol. [Epub 2020 Jul 22] 2020 Dec;267(12):3776–3784. DOI:10.1007/s00415-020-10090-4.
  • Westgate CS, Botfield HF, Alimajstorovic Z, et al. Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. JCI Insight. 2021 May 24;6(10):e145346. DOI:10.1172/jci.insight.145346.
  • Schiffer L, Arlt W, O’Reilly MW. Understanding the role of androgen action in female adipose tissue. Front Horm Res. 2019 Epub 2019 Sep 9;53:33–49. DOI:10.1159/000494901.
  • O’Reilly MW, Kempegowda P, Walsh M, et al. AKR1C3-mediated adipose androgen generation drives lipotoxicity in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2017 Sep 1;102(9):3327–3339. DOI:10.1210/jc.2017-00947.
  • Avisar I, Gaton DD, Dania H, et al. The prevalence of polycystic ovary syndrome in women with idiopathic intracranial hypertension. Scientifica (Cairo). [Epub 2012 Jul 11] 2012;2012:708042. DOI:10.6064/2012/708042
  • Thaller M, Adderley NJ, Subramanian A, et al. Co-morbid polycystic ovarian syndrome with idiopathic intracranial hypertension. Neuroophthalmology. 2023 Jan 10;47(1):49–52. DOI:10.1080/01658107.2022.2162089.
  • Hornby C, Mollan SP, Mitchell J, et al. What do transgender patients teach us about idiopathic intracranial hypertension? Neuroophthalmology. 2017 May 10;41(6):326–329. DOI:10.1080/01658107.2017.1316744.
  • Nayman T, Hébert M, Ospina LH. Idiopathic intracranial hypertension in a pediatric transgender patient. Am J Ophthalmol Case Rep. 2021 Sep 22;24:101208. DOI:10.1016/j.ajoc.2021.101208.
  • Alimajstorovic Z, Pascual-Baixauli E, Hawkes CA, et al. Cerebrospinal fluid dynamics modulation by diet and cytokines in rats. Fluids Barriers CNS. 2020;17(1):10.
  • Sinclair AJ, Walker EA, Burdon MA, et al. Cerebrospinal fluid corticosteroid levels and cortisol metabolism in patients with idiopathic intracranial hypertension: a link between 11beta-HSD1 and intracranial pressure regulation? J Clin Endocrinol Metab. 2010 DecSep[2010 8];95(12):5348–5356. Epub: 10.1210/jc.2010-0729
  • Markey KA, Uldall M, Botfield H, et al. Idiopathic intracranial hypertension, hormones, and 11β-hydroxysteroid dehydrogenases. J Pain Res. 2016 Apr 19;9:223–232. DOI:10.2147/JPR.S80824.
  • Westgate CSJ, Markey K, Mitchell JL, et al. Increased systemic and adipose 11β-HSD1 activity in idiopathic intracranial hypertension. Eur J Endocrinol. 2022 Jul 4;187(2):323–333. DOI:10.1530/EJE-22-0108.
  • Grech O, Clouter A, Mitchell JL, et al. Cognitive performance in idiopathic intracranial hypertension and relevance of intracranial pressure. Brain Comm. 2021;3(3):3fcab202. DOI:10.1093/braincomms/fcab202
  • Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition (beta version). Cephalalgia. 2013 Jul;33(9):629–808. DOI:10.1177/0333102413485658
  • Mollan SP, Wakerley BR, Alimajstorovic Z, et al. Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension. J Headache Pain. 2021 Oct 7;22(1):118. DOI:10.1186/s10194-021-01321-8.
  • Mollan SP, Hoffmann J, Sinclair AJ. Advances in the understanding of headache in idiopathic intracranial hypertension. Curr Opin Neurol. 2019 Feb;32(1):92–98. DOI:10.1097/WCO.0000000000000651.
  • Virdee J, Larcombe S, Vijay V, et al. Reviewing the recent developments in idiopathic intracranial hypertension. Ophthalmol Ther. [Epub 2020 Sep 9] 2020 Dec;9(4):767–781. DOI:10.1007/s40123-020-00296-0.
  • Mollan SP, Virdee JS, Bilton EJ, et al. Headache for ophthalmologists: current advances in headache understanding and management. Eye (Lond). [Epub 2021 Feb 12] 2021 Jun 35(6):1574–1586. DOI:10.1038/s41433-021-01421-4
  • Wakerley BR, Mollan SP, Sinclair AJ. Idiopathic intracranial hypertension: update on diagnosis and management. Clin Med. 2020 Jul;20(4):384–388.
  • Vijay V, Mollan SP, Mitchell JL, et al. Using optical coherence tomography as a surrogate of measurements of intracranial pressure in idiopathic intracranial hypertension. JAMA Ophthalmol. 2020 Dec 1;138(12):1264–1271. DOI:10.1001/jamaophthalmol.2020.4242.
  • Aojula A, Mollan SP, Horsburgh J, et al. Segmentation error in spectral domain optical coherence tomography measures of the retinal nerve fibre layer thickness in idiopathic intracranial hypertension. BMC Ophthalmol. 2017;17(1):257. DOI:10.1186/s12886-017-0652-7
  • Fraser C, Lueck CJ. Optical coherence tomography: a window to the brain? Pract Neurol. 2021;21(4):3130321.
  • Xie JS, Donaldson L, Margolin E. Papilledema: a review of etiology, pathophysiology, diagnosis, and management. Surv Ophthalmol. [Epub 2021 Nov 20] 2022 Jul;67(4):1135–1159. DOI:10.1016/j.survophthal.2021.11.007.
  • Sarrami AH, Bass DI, Rutman AM, et al. Idiopathic intracranial hypertension imaging approaches and the implications in patient management. British J Radiol. 2022;95(1136):1136.
  • Turay S, Kabakus N, Hanci F, et al. Cause or consequence: the relationship between cerebral venous thrombosis and idiopathic intracranial hypertension. Neurologist. 2019;24(5):155–160.
  • Onder H, Kisbet T. Neuroimaging findings in patients with idiopathic intracranial hypertension and cerebral venous thrombosis, and their association with clinical features. Neurological res. 2020;42(2):141–147.
  • Bidot S, Saindane AM, Peragallo JH, et al. Brain imaging in idiopathic intracranial hypertension. J Neuroophthalmol. 2015;35(4):4;400–411.
  • Skipper NT, Igra MS, Littlewood R, et al. Do optic canal dimensions measured on CT influence the degree of papilloedema and visual dysfunction in idiopathic intracranial hypertension? Neuroophthalmology. 2018 Jun 26;43(1):3–9. DOI:10.1080/01658107.2018.1483406.
  • Saindane AM, Bruce BB, Riggeal BD, et al. Association of MRI findings and visual outcome in idiopathic intracranial hypertension. AJR Am J Roentgenol. 2013 Aug;201(2):412–418. DOI:10.2214/AJR.12.9638.
  • ] Kuzan BN, Ilgın C, Kuzan TY, Dericioğlu V, Kahraman-Koytak P, Uluç K, Çimşit NÇ. Accuracy and reliability of magnetic resonance imaging in the diagnosis of idiopathic intracranial hypertension. Eur J Radiol. 2022 OctAug[Epub 2022 17];155:110491. DOI:10.1016/j.ejrad.2022.110491.
  • Prabhat N, Chandel S, Takkar DA, et al. Sensitivity and specificity of neuroimaging signs in patients with idiopathic intracranial hypertension. Neuroradiol J. [Epub 2021 Mar 8] 2021 Oct;34(5):421–427. DOI:10.1177/19714009211000623
  • Aung AB, Chen BS, Wicks J, et al. Presumptive idiopathic intracranial hypertension based on neuroimaging findings: a referral pattern study. J Neuroophthalmol. 2022 Jul 8;43(1): Epub ahead of print:55–62. DOI:10.1097/WNO.0000000000001660
  • Bateman DE, Wingrove B. Comparison of the range of lumbar cerebrospinal fluid pressure in adults with normal cerebrospinal fluid pressure and in idiopathic intracranial hypertension. J Neuroophthalmol. 2022 Mar 25;42(4):502–504.
  • Vosoughi AR, Margolin EA, Micieli JA. Can lumbar puncture be safely deferred in patients with mild presumed idiopathic intracranial hypertension? J Neuroophthalmol. 2021 Oct 22;42(4):505–508.
  • Scotton WJ, Mollan SP, Walters T, et al. Characterising the patient experience of diagnostic lumbar puncture in idiopathic intracranial hypertension: a cross-sectional online survey. BMJ Open. 2018 May 30;8(5):e020445.
  • Yiangou A, Mitchell J, Markey KA, et al. Therapeutic lumbar puncture for headache in idiopathic intracranial hypertension: minimal gain, is it worth the pain? Cephalalgia. 2019;39(2):245–253. DOI:10.1177/0333102418782192
  • Kilic K, Korsbæk JJ, Jensen RH, et al. Diagnosis of idiopathic intracranial hypertension - the importance of excluding secondary causes: a systematic review. Cephalalgia. [Epub 2021 Nov 25] 2022 May 42(6):524–541. DOI:10.1177/03331024211056580
  • Mollan S, Ball P, A K, et al. Idiopathic intracranial hypertension associated with iron deficiency anaemia: a lesson for management. Eur Neurol. 2009;62(2):105–108.
  • Benzimra JD, Simon S, Sinclair AJ, et al. Sight-threatening pseudotumour cerebri associated with excess vitamin a supplementation. Pract Neurol. 2015;15(1):72–73.
  • Sodhi A, Sheldon CA, Carleton B, et al. Oral fluoroquinolones and risk of secondary pseudotumor cerebri syndrome: nested case-control study. Neurology. 2017;22(89):792–795.
  • Mollan SP, Mytton J, Tsermoulas G, et al. Idiopathic intracranial hypertension: evaluation of admissions and emergency readmissions through the hospital episode statistic dataset between 2002–2020. Life. 2021;11(5):417.
  • Hyder YF, Homer V, Thaller M, et al. Defining the phenotype and prognosis of people with idiopathic intracranial hypertension after cerebrospinal fluid diversion surgery. Am J Ophthalmol. 2023 Jan 19:S0002-9394(23)p. 00026. DOI:10.1016/j.ajo.2023.01.016
  • Hamedani AG, Thibault DP, Revere KE, et al. Trends in the surgical treatment of pseudotumor cerebri syndrome in the United States. JAMA Netw Open. 2020 Dec 1;3(12):e2029669. DOI:10.1001/jamanetworkopen.2020.29669
  • Kalyvas A, Neromyliotis E, Koutsarnakis C, et al. A systematic review of surgical treatments of idiopathic intracranial hypertension (IIH). Neurosurg RevEpub. [2020 Apr 25] 2021 Apr 44(2):773–792. DOI:10.1007/s10143-020-01288-1
  • Kalyvas AV, Hughes M, Koutsarnakis C, et al. Efficacy, complications and cost of surgical interventions for idiopathic intracranial hypertension: a systematic review of the literature. Acta Neurochir (Wien). 2017;159(1):33–49.
  • Tsermoulas G, Thant KZ, Byrne ME, et al. The birmingham standardized idiopathic intracranial hypertension shunt protocol: technical note. World Neurosurg. 2022 Sep 9;167:147–151. Epub ahead of print. DOI:10.1016/j.wneu.2022.08.154
  • Galloway L, Karia K, White AM, et al. Cerebrospinal fluid shunting protocol for idiopathic intracranial hypertension for an improved revision rate. J Neurosurg. 2021 Oct;8:1–6. Epub ahead of print. DOI:10.1016/j.bas.2021.100757
  • Hagen SM, Wegener M, Toft PB, et al. Unilateral optic nerve sheath fenestration in idiopathic intracranial hypertension: a 6-month follow-up study on visual outcome and prognostic markers. Life (Basel). 2021 Jul 31;11(8):778.
  • Trucchi L, Cohen M, Nahon-Esteve S, et al. Optic nerve sheath fenestration: current status in France and comparison of 6 different surgical approaches. J Fr Ophtalmol. 2023 Feb;46(2):137–147. DOI:10.1016/j.jfo.2022.07.014
  • Jefferis JM, Littlewood RA, Pepper IM, et al. Optic nerve sheath fenestration via a supero-medial eyelid skin crease approach for the treatment of idiopathic intracranial hypertension in a UK population. Eye (Lond). 2021 May;35(5):1418–1426.
  • Asif H, Craven CL, Siddiqui AH, et al. Idiopathic intracranial hypertension: 120-day clinical, radiological, and manometric outcomes after stent insertion into the dural venous sinus. J Neurosurg. [Epub 2017 Oct 6] 2018 Sep;129(3):723–731. DOI:10.3171/2017.4.JNS162871
  • Toscano S, Lo Fermo S, Reggio E, et al. An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management. J Neurol. [Epub 2020 May 27] 2021 Sep;268(9):3249–3268. DOI:10.1007/s00415-020-09943-9
  • Mollan SP, Mitchell JL, Ottridge RS, et al. Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension: a randomized clinical trial. JAMA Neurol. 2021 Jun 1;78(6):678–686. DOI:10.1001/jamaneurol.2021.0659
  • Mollan SP, Mitchell JL, Yiangou A, et al. Association of amount of weight lost after bariatric surgery with intracranial pressure in women with idiopathic intracranial hypertension. Neurology. 2022 Sep 13Epub 2022 Jul 5;99(11):e1090–1099.
  • Sinclair AJ, Burdon MA, Nightingale, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ. 2010;341:c2701.
  • Dombrowski SU, Knittle K, Avenell A, et al. Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials. BMJ: British Medical Journal. 2014;348(may14 6):g2646.
  • Thaller M, Tsermoulas G, Sun R, et al. Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry. 2021;92(7):795–797.
  • Elliot L, Frew E, Mollan SP, et al. Cost-effectiveness of bariatric surgery versus community weight management to treat obesity-related idiopathic intracranial hypertension: evidence from a single-payer healthcare system. Surg Obes Relat Dis. [Epub 2021 Mar 30] 2021 Jul;17(7):1310–1316. DOI:10.1016/j.soard.2021.03.020
  • Barbuskaite D, Oernbo EK, Wardman JH, et al. Acetazolamide modulates intracranial pressure directly by its action on the cerebrospinal fluid secretion apparatus. Fluids Barriers CNS. 2022 Jun 29;19(1):53. DOI:10.1186/s12987-022-00348-6
  • Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014;311(16):1641–1651.
  • Ball AK, Howman A, Wheatley K, et al. A randomised controlled trial of treatment for idiopathic intracranial hypertension. J Neurol. 2011 May;258(5):874–881.
  • ten Hove MW, Friedman DI, Patel AD, et al. Safety and tolerability of acetazolamide in the idiopathic intracranial hypertension treatment trial. J Neuroophthalmol. 2016 Mar;36(1):13–19. DOI:10.1097/WNO.0000000000000322
  • British National Formulary – Acetazolamide. https://bnf.nice.org.uk/drug/acetazolamide.html. last accessed 27th Sep, 2022.
  • Hu C, Zhang Y, Tan G. Advances in topiramate as prophylactic treatment for migraine. Brain Behav. [Epub 2021 Sep 2] 2021 Oct;11(10):e2290. DOI:10.1002/brb3.2290
  • Celebisoy N, Gökçay F, Sirin H, et al. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand. 2007 Nov;116(5):322–327. DOI:10.1111/j.1600-0404.2007.00905.x
  • Mollan SP, Subramanian A, Perrins M, et al. Depression and anxiety in women with idiopathic intracranial hypertension compared to migraine: a matched controlled cohort study. Headache. 2023 Feb 7;63(2):290–298.
  • Mollan SP, Spitzer D, Nicholl DJ. Raised intracranial pressure in those presenting with headache. BMJ. 2018 Oct 4;363:k3252. DOI:10.1136/bmj.k3252
  • Grech O, Seneviratne SY, Alimajstorovic Z, et al. NucleaR magnetic resonance spectroscopy metabolomics in idiopathic intracranial hypertension to identify markers of disease and headache. Neurology. 2022 Sep 8;99(16):e1702–14.
  • Adderley NJ, Subramanian A, Perrins M, et al. Headache, opiate use, and prescribing trends in women with idiopathic intracranial hypertension: a population-based matched cohort stuDy. Neurology. 2022 Aug 19;99(18):e1968–78. DOI:10.1212/WNL.0000000000201064
  • Yiangou A, Mitchell JL, Fisher C, et al. Erenumab for headaches in idiopathic intracranial hypertension: a prospective open-label evaluation. Headache. 2021 Jan;61(1):157–169.
  • Yiangou A, Mitchell JL, Vijay V, et al. Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. J Headache Pain. 2020 Sep 25;21(1):116.
  • Sarkhosh K, Switzer NJ, El-Hadi M, et al. The impact of bariatric surgery on obstructive sleep apnea: a systematic review. Obes Surg. 2013 Mar;23(3):414–423. DOI:10.1007/s11695-012-0862-2
  • Yiangou A, Mitchell JL, Nicholls M, et al. Obstructive sleep apnoea in women with idiopathic intracranial hypertension: a sub-study of the idiopathic intracranial hypertension weight randomised controlled trial (IIH: wT). J Neurol. [Epub 2021 Aug 22] 2022 Apr;269(4):1945–1956. DOI:10.1007/s00415-021-10700-9
  • Knauert M, Naik S, Gillespie MB, et al. Clinical consequences and economic costs of untreated obstructive sleep apnea syndrome. World J Otorhinolaryngol Head Neck Surg. 2015 Sep 8;1(1):17–27. DOI:10.1016/j.wjorl.2015.08.001
  • Kok LT, Gnoni V, Muza R, et al. Prevalence and utility of overnight pulse oximetry as a screening tool for obstructive sleep apnoea in newly diagnosed idiopathic intracranial hypertension. Eye (Lond). 2022 Feb;24(3):1–6. Epub ahead of print. DOI:10.1038/s41433-022-01971-1
  • Thaller M, Homer V, Mollan SP, et al. Disease course and long-term outcomes in pregnant women with idiopathic intracranial hypertension: the iih prospective maternal health study. Neurology. 2023;100(15):e1598–1610. Feb 7. DOI:10.1212/WNL.0000000000206854
  • Thaller M, Wakerley BR, Abbott S, et al. Managing idiopathic intracranial hypertension in pregnancy: practical advice. Pract Neurol. [Epub 2022 Apr 21] 2022 Aug;22(4):295–300. DOI:10.1136/practneurol-2021-003152
  • Byth LA, Lust K, Jeffree RL, et al. Management of idiopathic intracranial hypertension in pregnancy. Obstet Med. 2022;15(3):160–167.
  • Falardeau J, Lobb BM, Golden S, et al. The use of acetazolamide during pregnancy in intracranial hypertension patients. J Neuroophthalmol. 2013 Mar;33(1):9–12. DOI:10.1097/WNO.0b013e3182594001
  • Weston J, Bromley R, Jackson CF, et al. Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child. Cochrane Database Syst Rev. 2016 Nov 7;11(11). CD010224. DOI:10.1002/14651858.CD010224.pub2
  • McAuliffe FM, Killeen SL, Jacob CM, et al. Management of prepregnancy, pregnancy, and postpartum obesity from the FIGO Pregnancy and Non-Communicable Diseases Committee: a FIGO (International Federation of Gynecology and Obstetrics) guideline. Int J Gynaecol Obstet. 2020 Sep;151(Suppl 1):16–36. DOI:10.1002/ijgo.13334
  • Thaller M, Mytton J, Wakerley BR, et al. Idiopathic intracranial hypertension: evaluation of births and fertility through the Hospital Episode Statistics dataset. BJOG. 2022 Nov;129(12):2019–2027. DOI:10.1111/1471-0528.17241
  • National Institute for Health and Care Excellence. Weight management before during and after pregnancy. London: Public health guideline; 2010. www.nice.org.uk/guidance/ph27
  • Chih A, Patel B. Idiopathic intracranial hypertension in pregnancy. Fed Pract. 2015 Nov;32(11):36–40.
  • Qureshi A, Virdee J, Tsermoulas G, et al. Optical coherence tomography confirms shunt malfunction and recurrence of raised intracranial pressure in optic atrophy. Br J Neurosurg. 2022 Apr;36(2):185–191.
  • Markey K, Mitchell J, Botfield H, et al. 11β-Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. Brain Commun. 2020 Jan 10;2(1):fcz050. DOI:10.1093/braincomms/fcz050
  • Hardy RS, Botfield H, Markey K, et al. 11βHSD1 inhibition with AZD4017 improves lipid profiles and lean muscle mass in idiopathic intracranial hypertension. J Clin Endocrinol Metab. 2021 Jan 1;106(1):174–187. DOI:10.1210/clinem/dgaa766
  • Mitchell J, Mollan S, Walker J, et al. A randomised controlled, trial of the GLP-1 receptor agonist exenatide in idiopathic intracranial hypertension. J Neurol Neurosurg Psychiatry. 2022;93(6):A98. DOI:10.1136/jnnp-2022-ABN.317
  • Mitchell JL, Buckham R, Lyons H, et al. Evaluation of diurnal and postural intracranial pressure employing telemetric monitoring in idiopathic intracranial hypertension. Fluids Barriers CNS. 2022 Nov 1;19(1):85. DOI:10.1186/s12987-022-00384-2
  • Behary P, Tharakan G, Alexiadou K, et al. Combined GLP-1, oxyntomodulin, and peptide yy improves body weight and glycemia in obesity and prediabetes/type 2 diabetes: a randomized, single-blinded, placebo-controlled study. Diabetes Care. 2019;42(8):1446–1453. DOI:10.2337/dc19-0449
  • Mollan S, Hemmings K, Herd CP, et al. What are the research priorities for idiopathic intracranial hypertension? A priority setting partnership between patients and healthcare professionals. BMJ Open. 2019 Mar 15;9(3):e026573.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.